The BioTech Strategist

About

Autor: Aisha Soraya Ahmad

  • Merck KGaA-Skyhawk RNA Splicing

    —

    von

    Aisha Soraya Ahmad
    in

    RNA Splicing Modulation: Analyzing the $2B Merck KGaA-Skyhawk Partnership and the Emergence of a New Therapeutic Modality The human genome contains roughly 20,000 protein-coding genes, yet our bodies produce over 100,000 distinct proteins. This mathematical impossibility becomes reality through RNA splicing, nature’s molecular editing system that rearranges genetic information like a film editor creating different…

  • How Tharimmune’s TH104 Navigated the FDA’s 505(b)(2) Pathway

    —

    von

    Aisha Soraya Ahmad
    in

    From Simulation to Market: How Tharimmune’s TH104 Navigated the FDA’s 505(b)(2) Pathway to Address a National Security Threat The synthetic opioid crisis has evolved far beyond a public health emergency. When a substance fifty times more potent than heroin can be synthesized in a garage and weaponized as an aerosol, the line between pharmaceutical and…

  • Kriya Therapeutics $313M Funding

    —

    von

    Aisha Soraya Ahmad
    in

    Kriya Therapeutics‘ $313M Series Funding: Decoding the Investment Thesis Behind Nine-Asset Gene Therapy Pipelines in a Challenging Market The gene therapy sector exists in a peculiar state of simultaneous crisis and opportunity. On one hand, safety concerns mount as Sarepta’s Elevidys faces scrutiny following patient deaths and the FDA restricts bluebird bio’s Skysona due to…